Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early
Status:
Completed
Trial end date:
2020-11-30
Target enrollment:
Participant gender:
Summary
Recent information appearing from different countries suggest that treatment of Coronavirus
disease 2019 (COVID-19) with hydroxychloroquine or with a combination of hydroxychloroquine
and azithromycin has either an indifferent effect on viral replication or substantial
cardiotoxicity. This is a clinical trial aiming to prove that addition of oral clarithromycin
to treatment regimen of COVID-19 is associated with early clinical improvement and
attenuation of the high inflammatory burden of the host. The study will not comprise a
placebo-comparator group since this is considered inappropriate in an era of a pandemic with
substantial global mortality.